Mirador Therapeutics launched with USD 400 million in seed funding. The round was led by ARCH Venture Partners, including initial investments from OrbiMed and Fairmount, with participation from Fidelity Management & Research Company, Sanofi Ventures, Point72, and Farallon Capital Management, among others.
The company expects to use the funds to develop several therapeutic initiatives focused on immune-mediated inflammatory and fibrotic conditions.
California-based Mirador Therapeutics intends to use its development platform, Mirador360, to combine data science and data on human genetics to integrate numerous patient molecular profiles to identify genetic links to immune-fibrotic diseases and discover novel therapeutic targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.